FibroGen to Report Second Quarter 2025 Financial Results
FibroGen (NASDAQ: FGEN) has scheduled its second quarter 2025 financial results announcement for Monday, August 11, 2025, after market close. The company will host a conference call and webcast presentation at 5:00 PM Eastern Time on the same day.
The event will feature the FibroGen management team presenting financial results and providing a business update, followed by a live Q&A session. Investors can access the audio webcast through the company's website, and dial-in details will be provided upon registration.
FibroGen (NASDAQ: FGEN) ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per luned¨¬ 11 agosto 2025, dopo la chiusura del mercato. La societ¨¤ terr¨¤ una conference call e una presentazione in webcast alle 17:00 ora della costa orientale degli Stati Uniti dello stesso giorno.
L'evento vedr¨¤ il team di gestione di FibroGen presentare i risultati finanziari e fornire un aggiornamento sull'attivit¨¤, seguito da una sessione di domande e risposte in diretta. Gli investitori potranno accedere all'audio webcast tramite il sito web dell'azienda, con i dettagli per la chiamata forniti al momento della registrazione.
FibroGen (NASDAQ: FGEN) ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el lunes 11 de agosto de 2025, despu¨¦s del cierre del mercado. La compa?¨ªa realizar¨¢ una llamada de conferencia y una presentaci¨®n en webcast a las 5:00 PM hora del Este del mismo d¨ªa.
El evento contar¨¢ con la participaci¨®n del equipo directivo de FibroGen, que presentar¨¢ los resultados financieros y proporcionar¨¢ una actualizaci¨®n del negocio, seguido de una sesi¨®n de preguntas y respuestas en vivo. Los inversores podr¨¢n acceder a la transmisi¨®n de audio a trav¨¦s del sitio web de la empresa, y se proporcionar¨¢n los detalles para la llamada tras la inscripci¨®n.
FibroGen (NASDAQ: FGEN)? 2025? 2?? ?? ?? ??? 2025? 8? 11? ??? ? ?? ?? ??????. ??? ?? ? ?? ??? ?? 5?? ???? ?? ???? ??????? ??? ?????.
?? ????? FibroGen ???? ?? ??? ???? ?? ??? ??????, ?? ??? ???? ??? ?????. ????? ?? ????? ?? ??? ????? ??? ? ???, ?? ? ?? ?? ??? ?????.
FibroGen (NASDAQ : FGEN) a programm¨¦ l'annonce de ses r¨¦sultats financiers du deuxi¨¨me trimestre 2025 pour le lundi 11 ao?t 2025, apr¨¨s la cl?ture des march¨¦s. La soci¨¦t¨¦ organisera une conf¨¦rence t¨¦l¨¦phonique et une pr¨¦sentation en webcast ¨¤ 17h00 heure de l'Est le m¨ºme jour.
L'¨¦v¨¦nement comprendra une pr¨¦sentation des r¨¦sultats financiers et une mise ¨¤ jour commerciale par l'¨¦quipe de direction de FibroGen, suivie d'une session de questions-r¨¦ponses en direct. Les investisseurs pourront acc¨¦der ¨¤ la diffusion audio via le site web de l'entreprise, avec les d¨¦tails d'acc¨¨s fournis lors de l'inscription.
FibroGen (NASDAQ: FGEN) hat die Ver?ffentlichung der Finanzergebnisse f¨¹r das zweite Quartal 2025 f¨¹r Montag, den 11. August 2025, nach B?rsenschluss, angek¨¹ndigt. Das Unternehmen wird am selben Tag um 17:00 Uhr Eastern Time eine Telefonkonferenz und eine Webcast-Pr?sentation abhalten.
Die Veranstaltung beinhaltet eine Pr?sentation der Finanzergebnisse und ein Gesch?ftsupdate durch das Management von FibroGen, gefolgt von einer Live-Fragerunde. Investoren k?nnen den Audio-Webcast ¨¹ber die Webseite des Unternehmens verfolgen; die Einwahldaten werden nach der Registrierung bereitgestellt.
- None.
- None.
SAN FRANCISCO, Aug. 04, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc.?(NASDAQ: FGEN) will announce second quarter 2025 financial results on?Monday, August 11?after the markets close.?FibroGen?will also conduct a conference call on that day at?5:00 PM Eastern Time?with the investment community to further detail the company's corporate and financial performance.
Conference Call and Webcast Presentation
The FibroGen?management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call?. To access the call by phone, please?, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the??page on FibroGen¡¯s website.
About?FibroGen
FibroGen, Inc.?is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (°®Èð׿?, EVRENZO?) is currently approved in?China,?Europe,?Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate a development plan for roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the?U.S.?FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46 is in development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit?.?
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
FAQ
When will FibroGen (FGEN) report Q2 2025 earnings?
What time is FibroGen's Q2 2025 earnings call?
How can investors access FibroGen's Q2 2025 earnings call?
Will there be a replay available of FibroGen's Q2 2025 earnings call?
